A Phase II Study of Ovarian Function Suppression And ExemesTane With or Without PalbocIclib in PreMenopausal Women With ER Positive / HER-2 Negative MetAstatic Breast Cancer
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Palbociclib (Primary) ; Exemestane; Goserelin
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms FATIMA
- 22 Jul 2021 Planned primary completion date changed from 1 Nov 2021 to 1 Dec 2021.
- 24 Aug 2019 Planned End Date changed from 1 Mar 2022 to 1 Dec 2023.
- 24 Aug 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Nov 2021.